EFX Shows Promising Liver Fibrosis Reduction in Phase 2B HARMONY Trial
96-week data from the HARMONY Phase 2b trial show Akero Therapeutics’ efruxifermin (EFX) yielded a 49% achievement rate for...
Invivyd and FDA Align on Accelerated Approval for COVID-19 Antibody
Invivyd has received FDA guidance on a streamlined Phase 2/3 trial design for VYD2311, its monoclonal antibody (mAb) candidate...
Lixte Biotech Oncology Pipeline Advances: Phase 1b/2 Trial Results Due 2H 2025
LIXTE Biotechnology Holdings (Nasdaq: LIXT) anticipates preliminary efficacy data in Q4 2025 from its Phase 1b/2 trial of LB-100,...
Largest Sickle Cell Study Unlocks Gene Therapy Pathways
Fifty1 AI Labs completed the most extensive study to date of sickle cellsickle cell disease (SCD), leveraging a decade...
Tiziana Doses First Patient in Trial of Intranasal Foralumab for MSA
Tiziana Life SciencesLife Sciences has dosed the first participant in a Phase 2a trial of intranasal foralumab for multiple...
Orchestra Biomed’s AVIM Therapy Shows Promise in Hypertension
Echocardiographic analysis from the MODERATO II study suggests that atrioventricular interval modulation (AVIM) therapy has a positive impact on...
Greywolf Therapeutics Initiates Dosing of First-in-Class Autoimmunity Treatment
Greywolf Therapeutics has dosed the first healthy volunteer in a Phase 1/2 trial of its oral ERAP1 inhibitor, GRWD0715,...
Ocugen, Inc. Receives Positive Scientific Advice From the EMA for Ocu410ST Gene Therapy for Stargardt Disease
Ocugen’s ongoing Phase 2/3 GARDian3 trial for Stargardt disease has received a positive opinion from the EMA’s Committee for...
Cognition Therapeutics and FDA Align on Zervimesine Trial for Alzheimer’s
Cognition Therapeutics received positive feedback from the FDA regarding its Phase 3 trial design for zervimesine (CT1812) in mild-to-moderate...
Aligos Doses First Subject in Phase 2b HBV Study
Aligos Therapeutics has initiated its Phase 2 B-SUPREME trial of ALG-000184, an oral capsid assembly modulator (CAM-E), in patients...